Psyence BioMed Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Through its strategic investment in PsyLabs, Psyence BioMed has established active ibogaine operations and manufacturing capabilities in Africa – the natural and original source of ibogaine. The Company believes it is among a limited number of organizations globally capable of producing natural, pharmaceutical-grade ibogaine at scale under pharmaceutical compliant GMP conditions.